Natera price target lowered to $55 from $70 at Credit Suisse

Credit Suisse analyst Dan Leonard lowered the firm’s price target on Natera to $55 from $70 and keeps an Outperform rating on the shares following quarterly results. The analyst highlights the company’s growth opportunities in minimal residual disease testing across multiple indications, as well as its continued leading position in reproductive health testing.